Axsome Therapeutics (NASDAQ: AXSM) and Exelixis (NASDAQ: EXEL) are emerging biotech companies with promising prospects despite their relatively low profiles. Axsome has demonstrated significant growth, particularly with its major depressive disorder treatment, Auvelity, which has driven a 63% year-over-year revenue increase to $171 million in the third quarter. Both companies are positioned for potential strong financial performance and stock market success as they head into the new year. Their ongoing clinical and regulatory advancements further enhance their attractiveness as investment opportunities.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
